Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.